• Dr. Hind Medyouf

    Tel.: +49 69 63395-540



    Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H*, Nowak D*. (2016)
    Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.
    Blood. Jun 6. pii: blood-2015-11-679167. [Epub ahead of print]

    Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T, Khandanpour C. (2016)
    Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
    Exp Hematol. May 20. pii: S0301-472X(16)30129-1. doi:10.1016/j.exphem. 2016.05.004. [Epub ahead of print]

    Kohrs N, Kolodziej S, Kuvardina ON, Herglotz J, Yillah J, Herkt S, Piechatzek A, Salinas Riester G, Lingner T, Wichmann C, Bonig H, Seifried E, Platzbecker U, Medyouf H, Grez M, Lausen J.(2016)
    MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.
    PLoS Genet. Mar 18;12(3):e1005946. doi: 10.1371/journal.pgen.1005946. eCollection




    Ekaterina B, Rauner M, Medyouf H, Theurl I, Bornhauser M , Hofbauer L, Platzbecker U. (2015) 
    Myelodysplasia is in the niche - novel concepts and emerging therapies.
    Leukemia. Feb 29(2):259-268.




    Ehninger A, Boch T, Medyouf H, Müdder K, et al. (2014)
    Loss of SPARC Protects Hematopoietic Stem Cells from Toxicity of Repeated Cycles of Chemotherapy by Accelerating their Return to Quiescence.
    Blood. Jun 26;123(26):4054-63. 

    Medyouf H, Mossner M, Jann JC, Nolte F, et al. (2014)
    Myelodysplastic Cells in Patients Re-program Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell-Niche Disease Unit.
    Cell Stem Cell. Jun 5;14(6):824-37.
    Preview: Raaijmakers M.H (2014) Cell Stem Cell. 13(6): 669-71.




    Medyouf H, Gusscott S, Wang H, Wai C, et al. (2011) 
    High Level IGF1R Expression is Required for Leukemia-Initiating Cell Activity in T-ALL and is Supported by Notch Signaling. 
    J Exp Med. 208(9): 1809-22. 

    Medyouf H, Gao X, Armstrong F, Gusscott S, et al. (2010)
    Acute T-cell Leukemias Remain Dependent on Notch Signaling Despite PTEN and INK4A/ARF Loss. 
    Blood. 115(6): 1175-84.

    Gerby B, Armstrong F, Brunet de la Grange P, Medyouf H, et al. (2010) 
    Optimized Gene Transfer into Human Primary Leukemic T-cells with NODSCID/Leukemia-Initiating-Cell activity. 
    Leukemia. 24(3): 646-9. 

    Medyouf H and Ghysdael J. (2008)
    The Calcineurin/NFAT Signaling Pathway: a Novel Therapeutic Target in Leukemia and Solid Tumors. 
    Cell Cycle 7(3): 297-303. 

    Medyouf H, Alcalde H, Berthier C, Guillemin MC, et al. (2007)
    Targeting Calcineurin Activation as a Therapeutic Strategy for Lymphoid Malignancies.
    Nat Medicine. (13): 736-741. 
    Preview: Müller MR, Rao A (2007) Nat. Med. 13(6): 669-71.

    Joliot V, Cormier F, Medyouf H, Alcalde H, et al. (2006)
    Constitutive STAT5 Activation Specifically Cooperates with the Loss of p53 Function in B-cell Lymphomagenesis. 
    Oncogene. 25(33): 4573-84.